DOTA-LM3
Based on 2 publication(s) in Google Scholar
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis. DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.37%
- CAS No.: 1192362-32-5
- Formule: C69H93ClN16O19S2
- Masse moléculaire:1550.16
-
Stockage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DOTA-LM3
MoreVoir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)
More
Activité biologique
|
RDC Peptide |
177Lu-DOTA-LM3 is tolerated. 177Lu-DOTA-LM3 in the whole body and in the kidneys, spleen, and metastases, resulting in higher mean absorbed organ and tumor doses[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1192362-32-5
-
Appearance Solid
-
Masse moléculaire 1550.16
-
Formule C69H93ClN16O19S2
-
Color White to off-white
-
Sequence
DOTA-[p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
H2O : ≥ 100 mg/mL (64.51 mM)
DMSO : 50 mg/mL (32.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhu W, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1613-1622. [Content Brief]
[2]. Baum RP, et al. First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med. 2021 Nov;62(11):1571-1581. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 0.6451 mL | 3.2255 mL | 6.4509 mL | 16.1274 mL |
| 5 mM | 0.1290 mL | 0.6451 mL | 1.2902 mL | 3.2255 mL | |
| 10 mM | 0.0645 mL | 0.3225 mL | 0.6451 mL | 1.6127 mL | |
| 15 mM | 0.0430 mL | 0.2150 mL | 0.4301 mL | 1.0752 mL | |
| 20 mM | 0.0323 mL | 0.1613 mL | 0.3225 mL | 0.8064 mL | |
| 25 mM | 0.0258 mL | 0.1290 mL | 0.2580 mL | 0.6451 mL | |
| 30 mM | 0.0215 mL | 0.1075 mL | 0.2150 mL | 0.5376 mL | |
| H2O | 40 mM | 0.0161 mL | 0.0806 mL | 0.1613 mL | 0.4032 mL |
| 50 mM | 0.0129 mL | 0.0645 mL | 0.1290 mL | 0.3225 mL | |
| 60 mM | 0.0108 mL | 0.0538 mL | 0.1075 mL | 0.2688 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
DOTA-LM3 Related Classifications
HY-P5126 Related Classifications
Powered by Bioz
- DOTA-LM3
- 1192362-32-5
- Radionuclide-Drug Conjugates (RDCs)
- Somatostatin Receptor
- somatostatin receptor
- LM3
- p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2
- sotopically labeled
- 177Lu-DOTA-LM3
- 68 Ga-DOTA-LM3
- biodistribution
- high tumor uptake
- good tumor retention
- safety
- DOTATOC-negative liver metastases
- pancreatic NET
- extensive tumor thrombosis
- Inhibitor
- inhibitor
- inhibit